Summary
4.39
-0.01
(-0.11%)
04/13/2026
CytomX Therapeutics, Inc. (CTMX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -0.11 | -0.23 | -10.04 | 1.15 | 30.65 | 787.59 | -34.87 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | D+ |
| Recommended Rating | Strong Sell |
| DCF | Strong Sell |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 4.39 | |
| Open | 4.36 | |
| High | 4.44 | |
| Low | 4.30 | |
| Volume | 4,467,185 | |
| Change | -0.01 | |
| Change % | -0.11 | |
| Avg Volume (20 Days) | 13,995,383 | |
| Volume/Avg Volume (20 Days) Ratio | 0.32 | |
| 52 Week Range | 0.48 - 8.21 | |
| Price vs 52 Week High | -46.59% | |
| Price vs 52 Week Low | 811.83% | |
| Range | 3.78 | |
| Gap Up/Down | -0.08 | |
Profitibility | ||
| Market Capitalization (Mln) | 653 | |
| Revenue per share | 0.4478 | |
| Net Income per share | -0.1021 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -43.0169 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
04/05 02:17 EST - defenseworld.net
CytomX Therapeutics (NASDAQ:CTMX) & Adagene (NASDAQ:ADAG) Financial Comparison
Adagene (NASDAQ: ADAG - Get Free Report) and CytomX Therapeutics (NASDAQ: CTMX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk,...
CytomX Therapeutics (NASDAQ:CTMX) & Adagene (NASDAQ:ADAG) Financial Comparison
Adagene (NASDAQ: ADAG - Get Free Report) and CytomX Therapeutics (NASDAQ: CTMX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk,...
03/31 03:33 EST - defenseworld.net
Assenagon Asset Management S.A. Sells 137,271 Shares of CytomX Therapeutics, Inc. $CTMX
Assenagon Asset Management S.A. decreased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 18.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 592,696 shares of the biotechnology company's stock...
Assenagon Asset Management S.A. Sells 137,271 Shares of CytomX Therapeutics, Inc. $CTMX
Assenagon Asset Management S.A. decreased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 18.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 592,696 shares of the biotechnology company's stock...
03/20 04:14 EST - defenseworld.net
CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) gapped up prior to trading on Thursday after Barclays raised their price target on the stock from $10.00 to $16.00. The stock had previously closed at $4.40, but opened at $4.51. Barclays currently has an overweight rating on the stock....
CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) gapped up prior to trading on Thursday after Barclays raised their price target on the stock from $10.00 to $16.00. The stock had previously closed at $4.40, but opened at $4.51. Barclays currently has an overweight rating on the stock....
03/18 13:06 EST - benzinga.com
Why Is CytomX Therapeutics Stock Falling On Wednesday?
On Tuesday, CytomX Therapeutics announced a public offering of 45.9 million shares at $5.30 per share, pre-funded warrants to purchase 1.179 million shares.
Why Is CytomX Therapeutics Stock Falling On Wednesday?
On Tuesday, CytomX Therapeutics announced a public offering of 45.9 million shares at $5.30 per share, pre-funded warrants to purchase 1.179 million shares.
03/18 10:03 EST - seekingalpha.com
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level
CytomX Therapeutics (CTMX) has generated significant excitement with strong early data for varsetatug masetecan in refractory colorectal cancer. Phase 1 results show 20–32% response rates and median PFS of 6.8–7.1 months, outperforming current treatments in this setting. CTMX is executing a...
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level
CytomX Therapeutics (CTMX) has generated significant excitement with strong early data for varsetatug masetecan in refractory colorectal cancer. Phase 1 results show 20–32% response rates and median PFS of 6.8–7.1 months, outperforming current treatments in this setting. CTMX is executing a...
03/17 22:46 EST - globenewswire.com
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten public offering of 45,990,567 shares of its common stock at a price to the...
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten public offering of 45,990,567 shares of its common stock at a price to the...
03/17 11:41 EST - zacks.com
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
03/17 04:02 EST - defenseworld.net
Boothbay Fund Management LLC Buys Shares of 1,237,057 CytomX Therapeutics, Inc. $CTMX
Boothbay Fund Management LLC purchased a new position in CytomX Therapeutics, Inc. (NASDAQ: CTMX) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 1,237,057 shares of the biotechnology company's stock, valued at approximately $3,946,000....
Boothbay Fund Management LLC Buys Shares of 1,237,057 CytomX Therapeutics, Inc. $CTMX
Boothbay Fund Management LLC purchased a new position in CytomX Therapeutics, Inc. (NASDAQ: CTMX) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 1,237,057 shares of the biotechnology company's stock, valued at approximately $3,946,000....
03/16 18:36 EST - fool.com
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
CytomX Therapeutics (CTMX +44.44%), a biotech company that develops conditionally activated biologics for cancer treatment, closed Monday at $6.75, up 44.23%. The stock is jumping after releasing Phase 1 Varseta-M data in metastatic colorectal cancer and subsequent upbeat analyst reactions.
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
CytomX Therapeutics (CTMX +44.44%), a biotech company that develops conditionally activated biologics for cancer treatment, closed Monday at $6.75, up 44.23%. The stock is jumping after releasing Phase 1 Varseta-M data in metastatic colorectal cancer and subsequent upbeat analyst reactions.
03/16 16:04 EST - globenewswire.com
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of common stock and, in lieu...
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of common stock and, in lieu...
03/16 13:59 EST - seekingalpha.com
CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade)
CytomX Therapeutics, Inc. receives a speculative Buy upgrade following promising new mCRC data for lead asset Varseta-M (CX-2051). Varseta-M shows a clear dose response and manageable safety profile with prophylactic measures, supporting the potential for a pivotal trial in 2027. CTMX valuation is...
CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade)
CytomX Therapeutics, Inc. receives a speculative Buy upgrade following promising new mCRC data for lead asset Varseta-M (CX-2051). Varseta-M shows a clear dose response and manageable safety profile with prophylactic measures, supporting the potential for a pivotal trial in 2027. CTMX valuation is...
03/16 12:38 EST - benzinga.com
Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally
The latest data revealed on Monday confirmed response rates in expansion cohorts of 32% at a 10 mg/kg Q3W dose and 20% at an 8.6 mg/kg Q3W dose, with an estimated progression-free survival of 7.1 months at the higher dose.
Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally
The latest data revealed on Monday confirmed response rates in expansion cohorts of 32% at a 10 mg/kg Q3W dose and 20% at an 8.6 mg/kg Q3W dose, with an estimated progression-free survival of 7.1 months at the higher dose.
03/16 12:03 EST - seekingalpha.com
CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript
CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript
CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript
CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript
03/16 09:26 EST - zacks.com
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.22 per share a year ago.
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.22 per share a year ago.
03/16 07:05 EST - globenewswire.com
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) -
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) -
03/16 07:00 EST - globenewswire.com
CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea rate of 10% in ongoing dose optimization cohorts - - FDA interactions targeted...
CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea rate of 10% in ongoing dose optimization cohorts - - FDA interactions targeted...
03/16 01:25 EST - benzinga.com
CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
CytomX Therapeutics, Inc. (NASDAQ: CTMX) will release its fourth-quarter earnings before the opening bell on Monday, March 16.
CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
CytomX Therapeutics, Inc. (NASDAQ: CTMX) will release its fourth-quarter earnings before the opening bell on Monday, March 16.
03/11 04:26 EST - defenseworld.net
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of “Moderate Buy” from Brokerages
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy...
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of “Moderate Buy” from Brokerages
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy...
03/05 01:14 EST - defenseworld.net
CytomX Therapeutics Target of Unusually Large Options Trading (NASDAQ:CTMX)
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 20,170 call options on the company. This is an increase of approximately 1,392% compared to the typical volume of 1,352 call options. Analysts...
CytomX Therapeutics Target of Unusually Large Options Trading (NASDAQ:CTMX)
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 20,170 call options on the company. This is an increase of approximately 1,392% compared to the typical volume of 1,352 call options. Analysts...
03/04 08:00 EST - globenewswire.com
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, 2026, before the open of U.S....
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, 2026, before the open of U.S....
Market News
×
Loading news…